Results of a Phase 3 study showed that sotatercept added to FDA-approved therapy improved the primary endpoint in six-minute walk distance and secondary efficacy outcome measures.

Sotatercept is manufactured by Merck (known as MSD outside of the United States and Canada). Merck announced the positive results from its Phase 3 STELLAR trial earlier this month. The clinical trial evaluated the safety and efficacy of sotatercept for adults with pulmonary arterial hypertension.

Merck was a sponsor of PHA 2022 International PH Conference and Scientific Sessions and the 2022 Pulmonary Hypertension Association (PHA) Medical Education Fund. It was a community-level sponsor of three PHA O2breathe walks this year.